RESUMO
Derangement of antioxidant levels in major depressive disorder had been correlated with oxidative damage. The effect of Selective Serotonin Re-Uptake Inhibitors on endogenous antioxidant uric acid levels in major depressive disorder has never been examined. This was a prospective; open labeled, parallel, 12 weeks study, in which serum uric acid levels and Hamilton Rating Scale for Depression score were estimated in age and sex matched thirty-six healthy and forty major depressive disorder subjects before and after fluoxetine and citalopram treatment. Significant decrease in serum uric acid (P<0.0001) was observed in newly diagnosed major depressive disorder subjects when compared to healthy subjects. The trend was reversed after 6 weeks more significantly after 12 weeks of treatment with improvement in Hamilton Rating Scale for Depression score. Also, Significant and negative correlation was found between Hamilton Rating Scale for Depression score and serum uric acid level (r= -0.864, P<0.001) after 12 weeks of treatment. Treatment with fluoxetine or citalopram reverses endogenous antioxidants like uric acid and improves Hamilton Rating Scale for Depression score in major depressive disorder.
RESUMO
RATIONALE: Several investigators implicated role of free radical-mediated pathology in schizophrenia. No study has ever examined the effect of vitamin C with atypical antipsychotics in the treatment of schizophrenia. OBJECTIVE: The aim of this study was to examine the effect of oral vitamin C with atypical antipsychotics on serum malondialdehyde (MDA), plasma ascorbic acid levels, and brief psychiatric rating scale (BPRS) score in schizophrenic patients. METHOD: Forty schizophrenic patients participated in a prospective, double-blind, placebo-controlled, noncrossover, 8-week study. The patients with schizophrenia were divided randomly into placebo and vitamin C group of 20 each. Serum MDA and plasma ascorbic acid were estimated by methods of Nischal and Aye, respectively. RESULT: Increased serum MDA and decreased plasma ascorbic acid levels were found in schizophrenic patients. These levels were reversed significantly after treatment with vitamin C along with atypical antipsychotics compared to placebo with atypical antipsychotics. BPRS change scores at 8 weeks improved statistically significant with vitamin C as compared to placebo. CONCLUSION: Oral supplementation of vitamin C with atypical antipsychotic reverses ascorbic acid levels, reduces oxidative stress, and improves BPRS score, hence both the drugs in combination can be used in the treatment of schizophrenia.
Assuntos
Antipsicóticos/uso terapêutico , Ácido Ascórbico/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Adulto , Análise de Variância , Antipsicóticos/sangue , Ácido Ascórbico/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Escalas de Graduação Psiquiátrica , Esquizofrenia/sangue , Esquizofrenia/complicações , Fatores de Tempo , Resultado do TratamentoRESUMO
Effect of pretreatment of intraperitoneally administered Ca-channel blockers Nifedipine (5, 10, 20 mg/kg). Verapamil (5, 10, 20 mg/kg) and Diltiazem (5, 10, 20 mg/kg) was studied on Haloperidol-induced catalepsy and Methamphetamine-induced stereotypy in albino rats. All these drugs reduced the onset of catalepsy, significantly increased the cataleptic score and delayed the onset and inhibited the Methamphetamine-induced stereotypy. The possible involvement of dopaminergic and adrenergic mechanisms and modification by Ca-channel blockers are discussed.